NCT07741981Recruiting
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- First submitted
- 29 Jun 2026
- Start date
- 20 Aug 2026
- Primary completion date
- 1 Nov 2036
- Lead sponsor
- Centre Hospitalier St Anne
- Diseases
- Schizophrenia, Depression, Bipolar disorder
- NCT number
- NCT07741981
What you commit to
- Study type: Interventional
- Planned participants: 700
- From 20 Aug 2026 to the primary completion date, 1 Nov 2036
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with major neurocognitive disorder diagnosed (dementia syndrome)
- Patient deprived of liberty by judicial or administrative decision. Patient in psychiatric care under constraints may be included.
Other
- Pregnant, laboring, or breastfeeding female patients
- For patients accepting the lumbar punction: patients who are unable to control themselves and are likely to engage in physical or violent behavior.
Who the study is looking for
- Patient aged ≥ 18 years old;
- Patient suffering from a psychiatric disorder according to DSM-5 criteria;
- Patient with drug-resistant disease according to the definition of the protocol
- Patient starting a new treatment for his pathology;
- Patient informed and having signed an informed consent;
- Patient covered by the social security system.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| GHU Paris Psychiatrie et Neurosciences Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.